Loading
LM-108 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer, with its target not yet stated publicly.
LM-108 is a monoclonal antibody developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical and LaNova Medicines. The sponsor describes its target as CCR8, which OnCo does not yet have a target page for. ClinicalTrials.gov describes the intervention as: LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumour sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody. Oxaliplatin is a third-ge. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07362186 (LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma), in pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer. The largest, NCT07362186, plans to enrol 400 participants with primary completion expected 2028-08-17. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.LM-108 binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"LM-108" OR ABSTRACT:"LM-108") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LM-108, not a curated reading list.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares LaNova Medicines and the tag pipeline.
Shares LaNova Medicines and the tag pipeline.
Shares LaNova Medicines and the tag pipeline.
Shares LaNova Medicines and the tag pipeline.
Shares LaNova Medicines and the tag pipeline.
Shares LaNova Medicines and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Pancreatic ductal adenocarcinoma and the tag pipeline.